Lv21
150 积分 2024-06-28 加入
Lenvatinib versus sorafenib second-line therapy in patients with hepatocellular carcinoma progressed to atezolizumab plus bevacizumab: a retrospective real-world study
10天前
已完结
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations
21天前
已完结
[Advances in targeted and immune therapies for hepatocellular carcinoma]
1个月前
已完结
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study
4个月前
已完结
皖公网安备34019202002308
